Skip to content
OpenCapital
Get started

Regeneron Pharmaceuticals REGN Lynozyfic — Revenue

Other product segments

Other products
$31.3M—

Similar metrics at other companies

Incyte logo
INCYZYNYZ — Total revenues
$41.39M+1,276%
Incyte logo
INCYOPZELURA — Total revenues
$143.02M+20.5%
BioMarin Pharmaceuticals logo
BMRNPALYNZIQ — Total revenues
$89.56M-4.0%
Biogen logo
BIIBZINBRYTA — Revenue
$0—
Incyte logo
INCYNet sales — Total revenues
$1.1B+19.8%
Incyte logo
INCYICLUSIG — Total revenues
$35.46M+20.0%

Other financials

Income statement

See full
Revenue$3.6B+19.0%
Operating income$642.9M+8.7%
Net income$727.2M-10.1%
EPS (diluted)$6.75-7.2%

Balance sheet

See full
Cash & equivalents$3.0B-4.0%
Total debt$2.7B+0.1%
Total equity$31.4B+6.9%
Total assets$40.9B+8.9%

Cash flow

See full
Operating cash flow$1.1B+3.2%
CapEx$230.6M+0.6%
Free cash flow$848.3M+4.0%

Valuation

See full
Market cap$63.95B+17.8%
Enterprise value$63.68B+18.1%
P/E14.5×+2.4×
P/S4.3×+0.4×

Profitability

See full
Gross margin93.9%—
Operating margin24.3%-2.9pp
Net margin29.6%-2.3pp
FCF margin27.6%+5.5pp

Returns & leverage

See full
Return on equity14.5%-1.4pp
Debt / equity0.1×0.0×
Current ratio3.6×-1.4×

Where this comes from

Reported directly by Regeneron Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Regeneron Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Regeneron Pharmaceuticals's lynozyfic — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Regeneron Pharmaceuticals's lynozyfic — revenue?
Regeneron Pharmaceuticals (REGN) reported lynozyfic — revenue of $11.2M in Q1 2026.
What does lynozyfic — revenue mean?
The total revenue generated from sales of the Lynozyfic product.
How do you interpret lynozyfic — revenue?
An increase indicates growing market share, successful commercial execution, or expanded clinical adoption, while a decrease may signal increased competition, patent expirations, or shifts in clinical treatment guidelines.
How does lynozyfic — revenue compare across companies?
Comparable to specific product revenue line items reported by other biopharmaceutical companies, often benchmarked against similar therapeutic class competitors.